The BARDA funding will support studies to validate the Melbourne, Australia-headquartered firm's flagship FebriDx rapid host-response respiratory infection test in low complexity settings and ...
The methods use heat to create bubbles that collect target particles. The bubbles leave behind concentrated deposits as they cool and shrink.
The company was accused of billing the federal government for medically unnecessary urine drug tests and providing kickbacks to physicians.
The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback